Pharmac is seeking public feedback on a proposal to simplify the criteria for people to receive Covid-19 antiviral medicines.

Center at UCSF is pioneering the development of potent drug candidates aimed at preventing future coronavirus pandemics.

Each day of delayed antiviral receipt raised the risk of hospitalization or death 17.9%, but there was no association between ...

Researchers have developed a new treatment formula—known as GS-1—that could reduce the symptoms and contagiousness of the ...

A single dose of the antiviral baloxavir marboxil (Xofluza) led to a lower incidence of influenza virus transmission to ...

ETH47 is a first-in-class mRNA antiviral therapy with broad-spectrum potential The project will generate key preclinical and ...

AVI-4303, which is a C5 benzotriazole analog, exhibited ten-fold higher potency than AVI-3318. Comparatively, N1 propargyl ...

Altria's dividend yield is 7%, even as it trades at 11 times estimated earnings over the next 12 months – a 40% premium to ...

Dr. Kate Knobil joins the biotech as it looks to combat a viral infection that can be dangerous to patients with the lung ...

ENA Respiratory, a clinical-stage pharmaceutical company developing antiviral host defence enhancers to minimize the impact ...

Artificial intelligence algorithms have now been combined with traditional laboratory methods to uncover promising drug leads against human enterovirus 71 (EV71), the pathogen behind most cases of ...